Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4).

作者: H. Murakami , T. Tamura , T. Takahashi , H. Nokihara , T. Naito

DOI: 10.1007/S00280-011-1738-1

关键词:

摘要: Purpose This Phase I study determined the maximum-tolerated dose (MTD) of afatinib (Afatinib is an investigational compound and its safety efficacy have not yet been established) (BIBW 2992; trade name approved by FDA), irreversible inhibitor epidermal growth factor receptor (EGFR)/human (HER)1 2, up to a 50 mg/day in advanced non-small cell lung cancer (NSCLC), establish recommended for II.

参考文章(22)
Nancy E. Hynes, Heidi A. Lane, ERBB receptors and cancer: the complexity of targeted inhibitors. Nature Reviews Cancer. ,vol. 5, pp. 341- 354 ,(2005) , 10.1038/NRC1609
Alexa B. Turke, Kreshnik Zejnullahu, Yi-Long Wu, Youngchul Song, Dora Dias-Santagata, Eugene Lifshits, Luca Toschi, Andrew Rogers, Tony Mok, Lecia Sequist, Neal I. Lindeman, Carly Murphy, Sara Akhavanfard, Beow Y. Yeap, Yun Xiao, Marzia Capelletti, A. John Iafrate, Charles Lee, James G. Christensen, Jeffrey A. Engelman, Pasi A. Jänne, Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC Cancer Cell. ,vol. 17, pp. 77- 88 ,(2010) , 10.1016/J.CCR.2009.11.022
James Spicer, Hilary Calvert, Laura Vidal, Fathi Azribi, Rebecca Perrett, Mehdi Shahidi, Graham Temple, Andrew Futreal, Johann De Bono, Ruth Plummer, D7-02: Activity of BIBW2992, an oral irreversible dual EGFR/HER2 inhibitor, in non-small cell lung cancer (NSCLC) with mutated EGFR Journal of Thoracic Oncology. ,vol. 2, pp. S410- ,(2007) , 10.1097/01.JTO.0000283293.26207.0A
Giuseppe Giaccone, Jose Antonio Rodriguez, EGFR inhibitors: what have we learned from the treatment of lung cancer? Nature Clinical Practice Oncology. ,vol. 2, pp. 554- 561 ,(2005) , 10.1038/NCPONC0341
Bruce E. Johnson, David Jackman, Pasi A. Jänne, Impact of EGFR mutations on treatment of non-small cell lung cancer Cancer Chemotherapy and Pharmacology. ,vol. 58, pp. 5- 9 ,(2006) , 10.1007/S00280-006-0309-3
James H. Doroshow, Targeting EGFR in non-small-cell lung cancer. The New England Journal of Medicine. ,vol. 353, pp. 200- 202 ,(2005) , 10.1056/NEJME058113
R. Plummer, L. Vidal, R. Perrett, J. Spicer, P. Stopfer, M. Shahidi, G. Temple, A. Futreal, H. Calvert, J. de Bono, 703 POSTER A phase I and pharmacokinetic (PK) study of BIBW 2992, an oral irreversible dual EGFR/HER2 inhibitor Ejc Supplements. ,vol. 5, pp. 108- ,(2007) , 10.1016/S1359-6349(07)70502-5
D Li, L Ambrogio, T Shimamura, S Kubo, M Takahashi, L R Chirieac, R F Padera, G I Shapiro, A Baum, F Himmelsbach, W J Rettig, M Meyerson, F Solca, H Greulich, K-K Wong, BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. ,vol. 27, pp. 4702- 4711 ,(2008) , 10.1038/ONC.2008.109
David S. Salomon, Ralf Brandt, Fortunato Ciardiello, Nicola Normanno, Epidermal growth factor-related peptides and their receptors in human malignancies Critical Reviews in Oncology Hematology. ,vol. 19, pp. 183- 232 ,(1995) , 10.1016/1040-8428(94)00144-I
R. Plummer, L. Vidal, L. Li, H. Shaw, R. Perrett, M. Shahidi, A. Amelsberg, G. Temple, H. Calvert, J. de Bono, 573 POSTER Phase I study of BIBW2992, an oral irreversible dual EGFR/HER2 inhibitor, showing activity in tumors with mutated EGFR Ejc Supplements. ,vol. 4, pp. 173- 174 ,(2006) , 10.1016/S1359-6349(06)70578-X